/SAR.L
SAR.L Stock - Sareum Holdings plc
Healthcare|BiotechnologyLSE
$15.50-4.62%
$0.75 (-4.62%) • Dec 22
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.53
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $17.05
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SAR.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.35 – $15.65
TARGET (TP)$17.82
STOP LOSS$14.26
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.87
52W High$29.00
52W Low$9.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-1,000 | $-1,000 | $-2,000 | $-1,088 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,380,000 | $-4,633,000 | $-4,024,000 | $-2,580,000 | $-1,875,050 |
| Net Income | $-4,438,000 | $-3,420,000 | $-3,192,000 | $-2,172,000 | $-1,500,383 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.04 | $-0.04 | $-0.05 | $-0.03 | $-0.02 |
Company Overview
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SAR.LBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q1 2025
EPS Surprise History
Q2 21
No data
Q4 21
No data
Q2 22
No data
Q1 23
No data
Q4 23
No data
Q1 24
No data
Q4 24
No data
Q1 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | — | — | — | — |
Q4 2025 | Oct 23, 2025 | — | — | — | — |
Q1 2025 | Mar 25, 2025 | — | $-0.01 | — | — |
Q4 2024 | Oct 29, 2024 | — | $-0.01 | — | — |
Q1 2024 | Mar 28, 2024 | — | $-0.04 | — | — |
Q4 2023 | Oct 9, 2023 | — | $-0.03 | — | — |
Q1 2023 | Mar 22, 2023 | — | $-0.02 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.02 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.01 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.01 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.01 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.01 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.01 | — | — |
Q2 2017 | Jun 30, 2017 | — | $0.00 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.00 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SAR.L
What is SAR.L's current stock price?
Sareum Holdings plc (SAR.L) is currently trading at $15.50 per share. The stock has moved -4.62% today.
What is the analyst price target for SAR.L?
No analyst price targets are currently available for this stock.
What sector is Sareum Holdings plc in?
Sareum Holdings plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the LSE exchange.
What is SAR.L's market cap?
Sareum Holdings plc has a market capitalization of $0.02 billion, making it a small-cap company.
Does SAR.L pay dividends?
No, Sareum Holdings plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPTA.L
Aptamer Group plc
$0.80
Mkt Cap: $2.2B
AREC.L
Arecor Therapeutics plc
$80.50
Mkt Cap: $3.0B
COG.L
Cambridge Cognition Holdings Plc
$28.50
Mkt Cap: $1.2B
FAB.L
Fusion Antibodies plc
$13.00
Mkt Cap: $1.5B
GENF.L
Genflow Biosciences plc
$1.80
Mkt Cap: $0.9B
IHC.L
Inspiration Healthcare Group plc
$15.25
Mkt Cap: $1.4B
IXI.L
IXICO plc
$11.75
Mkt Cap: $1.1B
OPTI.L
OptiBiotix Health Plc
$6.75
Mkt Cap: $0.7B
POLB.L
Poolbeg Pharma PLC
$4.00
Mkt Cap: $2.8B
RENX.L
Renalytix Plc
$6.25
Mkt Cap: $2.1B
Explore stocks similar to SAR.L for comparison